Type I and II IFNs inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T antigens.
about
Merkel cell carcinoma of the head and neck: pathogenesis, current and emerging treatment optionsMerkel Cell Carcinoma: Epidemiology, Target, and TherapyThe role of Merkel cell polyomavirus and other human polyomaviruses in emerging hallmarks of cancerEpigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinomaMerkel cell polyomavirus: molecular insights into the most recently discovered human tumour virus.Trichodysplasia spinulosa-associated polyomavirus (TSV) and Merkel cell polyomavirus: correlation between humoral and cellular immunity stronger with TSVLarge T and small T antigens of Merkel cell polyomavirus.The HSP70 modulator MAL3-101 inhibits Merkel cell carcinoma.Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinomaThe role of the immune response in merkel cell carcinoma.Proposal for publishing and parallel reporting of case reports on adverse drug reactions to authorities by physicians.MCV and Merkel cell carcinoma: a molecular success story.Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinomaHuman Merkel cell polyomavirus: virological background and clinical implications.Merkel cell carcinoma: Do you know your guidelines?Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinomaImmunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma.Interaction between Merkel cell carcinoma and the immune system: Pathogenetic and therapeutic implications.Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.Merkel Cell Polyomavirus Small T Antigen Drives Cell Motility via Rho-GTPase-Induced Filopodium Formation.Complete spontaneous regression of merkel cell carcinoma.
P2860
Q26796421-7CD8D421-CF3F-481F-9150-5A365CB1D9E8Q26824521-1142557E-7959-4DF7-856C-01E53D7A7D61Q28083883-8E1FFA55-0F77-46D4-949D-4751A236864DQ33720183-A9BDB3DA-7B3F-4F2D-B522-5A5EE7A60AF5Q34309882-98307D9B-49C3-44F7-8482-6B97706B07BEQ34430041-A2925E7D-2B7D-4B72-B81A-C622F71D5C39Q34462768-69B7963E-CCA3-409A-8E35-A04997E79D0CQ35138259-D0797BE0-9B4E-45C4-A070-BB717250236DQ36605917-CAE16DF3-9FB3-4325-8346-005AE38EF7F3Q37061729-D89212A9-E20A-4326-9C25-B63B3578AAC3Q37323908-F6C30D28-B138-4639-8CAD-236BEE9C1678Q38019683-84A79EE4-E4C2-4B4C-9F39-CE450F4FF75EQ38084205-4617234B-44ED-4A5E-AEF6-F7CBEB8DD1A9Q38115562-359A13A9-4B2F-41D5-80DF-5A9D8DC2853AQ38682926-4F573AC8-9799-4B78-8862-612B75D5566CQ38887303-F35FAF10-AFE3-4EC9-B917-99427A5514A1Q38966773-67D83428-440E-4220-97F2-4971340405C1Q40289983-C56445AB-CB64-4FDD-A241-E616D34878A0Q47097746-76AA6DD5-0274-4C87-B26A-ED061A5A4B24Q47571383-0B7932F8-670B-4BCB-8725-2FE32F5A29F1Q47576945-B3C328C2-E7B8-4604-8D15-334F779FF3F4Q51317758-D31956EC-8F37-4338-B27C-A8BD8F3F23E0
P2860
Type I and II IFNs inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T antigens.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Type I and II IFNs inhibit Mer ...... cell polyomavirus T antigens.
@en
Type I and II IFNs inhibit Mer ...... cell polyomavirus T antigens.
@nl
type
label
Type I and II IFNs inhibit Mer ...... cell polyomavirus T antigens.
@en
Type I and II IFNs inhibit Mer ...... cell polyomavirus T antigens.
@nl
prefLabel
Type I and II IFNs inhibit Mer ...... cell polyomavirus T antigens.
@en
Type I and II IFNs inhibit Mer ...... cell polyomavirus T antigens.
@nl
P2093
P1433
P1476
Type I and II IFNs inhibit Mer ...... l cell polyomavirus T antigens
@en
P2093
Christoph Willmes
David Schrama
Jürgen C Becker
Lena Völkert
Miriam Alb
P304
P356
10.1158/0008-5472.CAN-11-2651
P407
P577
2012-03-02T00:00:00Z